Epizyme Has 'Aggressive' Plans For Accelerated Tazemetostat Approval
This article was originally published in Scrip
Executive Summary
A year after losing its big pharma partner, epigenetic cancer therapy-focused Epizyme Inc. used its quarterly earnings call on March 9 to outline a four-step strategy for becoming a commercial company, expanding the potential uses for lead candidate tazemetostat (EPZ-6438, aka taz) and bringing at least three novel proprietary cancer candidates into clinical development by 2020.
You may also be interested in...
Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications
Accelerated approval in epithelioid sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.